法尼甾体X受体
小异二聚体伴侣
胰岛素抵抗
内科学
内分泌学
交易激励
非酒精性脂肪肝
核受体
硼胆酸
脂肪肝
癌症研究
过氧化物酶体增殖物激活受体
医学
化学
胰岛素
转录因子
受体
疾病
生物化学
基因
兴奋剂
作者
Sunmi Seok,Hao Sun,Young‐Chae Kim,Byron Kemper,Jongsook Kim Kemper
出处
期刊:Diabetes
[American Diabetes Association]
日期:2020-12-16
卷期号:70 (3): 733-744
被引量:32
摘要
Aberrantly elevated expression in obesity of microRNAs (miRNAs), including the miRNA miR-802, contributes to obesity-associated metabolic complications, but the mechanisms underlying the elevated expression are unclear. Farnesoid X receptor (FXR), a key regulator of hepatic energy metabolism, has potential for treatment of obesity-related diseases. We examined whether a nuclear receptor cascade involving FXR and FXR-induced small heterodimer partner (SHP) regulates expression of miR-802 to maintain glucose and lipid homeostasis. Hepatic miR-802 levels are increased in FXR-knockout (KO) or SHP-KO mice and are decreased by activation of FXR in a SHP-dependent manner. Mechanistically, transactivation of miR-802 by aromatic hydrocarbon receptor (AHR) is inhibited by SHP. In obese mice, activation of FXR by obeticholic acid treatment reduced miR-802 levels and improved insulin resistance and hepatosteatosis, but these beneficial effects were largely abolished by overexpression of miR-802. In patients with nonalcoholic fatty liver disease (NAFLD) and in obese mice, occupancy of SHP is reduced and that of AHR is modestly increased at the miR-802 promoter, consistent with elevated hepatic miR-802 expression. These results demonstrate that normal inhibition of miR-802 by FXR-SHP is defective in obesity, resulting in increased miR-802 levels, insulin resistance, and fatty liver. This FXR-SHP-miR-802 pathway may present novel targets for treating type 2 diabetes and NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI